Regeneron R2810-Onc-1788- A Randomized, Placebo-Controlled, Double-Blind Study Of Adjuvant Cemiplimab Versus Placebo After Surgery And Radiation Therapy In Patients With High Risk Cutaneous Squamous Cell Carcinoma
Posted Date: Jul 8, 2020
- Investigator: Rekha Chaudhary
- Specialties: Cancer, Oncology, Skin Cancer
- Type of Study: Drug
The primary goal is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT).
Criteria:
To Be Eligible: Must Have Diagnosis Of High Risk Cscc, Ecog =1, Post-Operative Rt Complete Within 2 To 6 Weeks, No Sccs Arising In Non-Cutaneous Sites, No Other Concurrent Malignancy Within 3 Years, No Prior Systemic Immunotherapy For Cscc, No Allogeneic Stem Cell Transplantation, No Current Or Recent Infection Or Comorbidity That Could Impact Study Treatment
Keywords:
Cscc, Skin Cancer, Cutaneous Squamous Cell Carcinoma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com